Physician profile
Daniel E Banach
NPI 1114913787
$3,910.60
in general payments reported to CMS, 2019-2025
35 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.75 · 2020: $488 · 2021: $571 · 2022: $645 · 2023: $675 · 2024: $774 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.67 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $380.40 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.95 | 2020-2025 | Xifaxan, Relistor |
| Lilly USA, LLC | $309.83 | 2020-2022 | |
| Novo Nordisk INC | $269.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $249.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $201.67 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $195.09 | 2020-2024 | Farxiga, Airsupra |
| Abbott Laboratories | $113.08 | 2021-2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $106.52 | 2020-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.92 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $93.17 | 2022-2023 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $81.76 | 2022 | |
| Exact Sciences Corporation | $80.04 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $68.38 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $60.72 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $53.65 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.30 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $49.64 | 2024 | Voquezna |
| Tolmar, INC. | $46.14 | 2024 | |
| Intuitive Surgical, INC. | $44.93 | 2025 | |
| Dexcom, INC. | $38.27 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $36.52 | 2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $33.93 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $33.20 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $22.95 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $21.41 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $18.59 | 2024 | Eliquis |
| Ibsa Pharma INC. | $18.05 | 2025 | Licart, Flector, Tirosint |
| Bayer Healthcare Pharmaceuticals INC. | $16.79 | 2025 | |
| Tonix Medicines, INC. | $16.63 | 2025 | Tonmya |
| Scilex Pharmaceuticals INC. | $16.52 | 2023 | Ztlido |
| Amarin Pharma, INC. | $16.01 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.98 | 2025 | Zoryve |
| Allergan, INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Banach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.